Leuprolide acetate Lupron Depot

The W /0/W emulsion technique has been also employed to encapsulate variety of drug compounds, including adriamycin and tobramycin, leuprolide acetate (Lupron Depot )15,20, nucleotides, thyrotropin-releasing hormone, growth hormone, RNA, and calcitonin. ... 

Leucovorin Wellcovorin -GlaxoSmithkIine, and others) Leuprolide acetate (Lupron, Lupron Depot - TAP, and others)... 

Lupron Depot PLA Leuprolide acetate Prostate cancer, endometreosis... 

Lupron Depot (leuprollde acetate for depot suspension) biodegradable polymeric particles capable of continuously delivering leuprolide for 1, 3, or 4 months for gynecological or urological disorders. 

Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis A 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998 91 16-24. 

Leuprolide acetate, a synthetic nonapeptide, is prescribed for the treatment of metastatic prostate cancer and endometriosis. Leuprolide acetate is presented in a number of injectable dosage forms including Lupron sterile solution for subcutaneous administration (1 and 5 mg mL 1) and Lupron depot controlled release formulation for intramuscular injection (3.75 and 7.5 mg). Zheng and Fulu [106] have evaluated the in vivo effect of leuprolide loaded micro emulsions on the genital organs of the male and female rats. In the preliminary pharmacokinetic studies, oral microemulsions of leuprolide administration resulted in 10-fold higher plasma levels of leuprolide as compared to that of saline solution (Fig. 9.4). 

Polymeric micropsheres, particularly those prepared from the biodegradable polylactide/ polyglycolide polymers, have been widely investigated as a means to achieve sustained parenteral drug delivery. The advantage of formulating the polymeric matrix as microspheres is the ability to administer them via a conventional needle and syringe as a suspension formulation, rather than as an implant (see below). Lupron depot formulations are available which can provide therapeutic blood levels of leuprolide acetate for up to four months. These products are presented as lyophilized polylactic acid microspheres which are reconstituted to form a suspension prior to administration. 

Leuprolide acetate/poly(DL-lactide-co-glycolide) Lupron Depot , Takeda Chemical Industries Endometriosis... 

Microsphere PLA Lupron Depot Leuprolide acetate Peptide hormone cancer and Alzheimer s... 

Leuprolide acetate (S) Lupron Depot Takeda-Abbott... 

Okada and co-workers (1988,1989,1991) and Ogawa etal. (1988) have also described a 75 25 PLGA microencapsulated 30-day release system for the delivery of another LHRH analog leuproUde acetate [(D-Leu , Pro NEt)-LHRH Lupron Depot , Takeda-Abbott], Their results indicate that a single injection of microcapsules maintains constant and effective serum levels of the analog for one month. Sufficient therapeutic efficacy in the treatment of advanced prostatic cancer has also been shown for leuprolide acetate, and the product has recently been approved for use by the U.S. Food and Drug Administration (Lupron Depot , 7.5mg PDR, 1994). This treatment has also shown to cause a dramatic regression of... 

Controlled Release of Peptides and Proteins. Sustained release applications are especially useful for proteins/peptides because of their short half-lives (62). This concept was first utilized commercially in Lupron Depot, which was introduced as a sustained release formulation of a lutenizing hormone-releasing hormone (LHRH), leuprolide acetate, with poly(lactic acid) as the polymer (63). Following the success of Lupron Depot, other sustained release formulations of LHRH analogues have also been commercialized, including Zoladex wherein the LHRH peptide is encapsulated in PLA-extruded rods, and Trelstar depot wherein the peptide is encapsulated in PLGA polymer matrices. 

Lupron Depot Leuprolide acetate TAP Prostate cancer Marketed... 

---